Drug intelligence / Profile preview

colchicine + doxycycline

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination of colchicine, an anti-inflammatory medication used primarily for gout and familial Mediterranean fever, and doxycycline, a tetracycline antibiotic used to treat various bacterial infections. Colchicine works by blocking inflammatory processes during gout attacks, while doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.

Targets

Bacterial RibosomeTUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on colchicine + doxycycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on colchicine + doxycycline.

Explore the full profile